Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   29/11/2024
11,75 USD (+0,60%)
(+0,60%)   29/11/2024

13 november 2024 · Alvotech Reports Financial Results for the First Nine Months of 2024 · Persbericht

7 november 2024 · Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 · Persbericht

4 november 2024 · European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) · Persbericht

30 oktober 2024 · Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET · Persbericht

25 oktober 2024 · Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 · Persbericht

22 oktober 2024 · Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) · Persbericht

10 oktober 2024 · European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® · Persbericht

25 september 2024 · Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® · Persbericht

26 augustus 2024 · Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

15 augustus 2024 · Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 · Persbericht

15 augustus 2024 · European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) · Persbericht

1 augustus 2024 · Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET · Persbericht

22 juli 2024 · STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe · Persbericht

11 juli 2024 · Alvotech Announces Closing of Private Debt Financing · Persbericht

2 juli 2024 · Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® · Persbericht

1 juli 2024 · Alvotech Issues New Shares to Holders of Convertible Bonds · Persbericht

1 juli 2024 · Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 · Persbericht

26 juni 2024 · Alvotech Receives Conversion Notices for Majority of Convertible Bonds · Persbericht

18 juni 2024 · Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe · Persbericht

11 juni 2024 · Alvotech and STADA add to Strategic Alliance through Denosumab Partnership · Persbericht

Mijn selecties